43 results on '"Snauwaert S"'
Search Results
2. Diagnostic utility of the lymphoid screening tube supplemented with TRBC1 for the assessment of T‐cell clonality
- Author
-
Blomme, S., primary, Nollet, F., additional, Boeckx, N., additional, Cauwelier, B., additional, Snauwaert, S., additional, and Emmerechts, J., additional
- Published
- 2023
- Full Text
- View/download PDF
3. P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE
- Author
-
Clausen, M. R., primary, Offner, F., additional, Belada, D., additional, Brody, J., additional, Linton, K. M., additional, Karimi, Y., additional, Cordoba, R., additional, Snauwaert, S., additional, Abbas, A., additional, Wang, L., additional, Wu, J., additional, Elliott, B., additional, and Falchi, L., additional
- Published
- 2022
- Full Text
- View/download PDF
4. PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
- Author
-
Hamadani, M., primary, Linhares, Y., additional, Gandhi, M. D., additional, Chung, M., additional, Adamis, H., additional, Ungar, D., additional, Carlo-Stella, C., additional, Kingsley, E., additional, Depaus, J., additional, Snauwaert, S., additional, Kwiatek, M., additional, and López-Jiménez, J., additional
- Published
- 2022
- Full Text
- View/download PDF
5. DIAGNOSIS AND TREATMENT OF PERIPHERAL T-CELL LYMPHOMAS: UPDATE RECOMMENDATIONS OF THE BELGIAN HEMATOLOGY SOCIETY (BHS)
- Author
-
UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Wolfromm, A, Bailly, S, Van Den Neste, E, André, Marc, Saevels, K, Antoine Poirel, H, Tousseyn, T, Van Hende, V, Snauwaert, S, Janssens, A, Jacquy, C, Bonnet, C, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Wolfromm, A, Bailly, S, Van Den Neste, E, André, Marc, Saevels, K, Antoine Poirel, H, Tousseyn, T, Van Hende, V, Snauwaert, S, Janssens, A, Jacquy, C, and Bonnet, C
- Abstract
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive diseases associated with poor outcomes. Recent progress in understanding of the biology and pathogenesis based on molecular profiling and next-generation sequencing has led to the introduction of new provisional entities in the World Health Organization (WHO) classification system of 2017 and to the emergence of new drugs.1 Previous Belgian guidelines were published in 2013.2 This review will discuss the diagnosis, work-up and treatment of PTCL including these advances as well as the limitation of the availability of drugs according to the Belgian reimbursement rules.
- Published
- 2022
6. BHS guidelines on supportive care in lymphoma : Part 2
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Janssens, M, Saelvels, K, Vergote, V, Lemmens, J, Bailly, S, Janssens, A, Snauwaert, S, André, Marc, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Janssens, M, Saelvels, K, Vergote, V, Lemmens, J, Bailly, S, Janssens, A, Snauwaert, S, and André, Marc
- Abstract
Besides disease-directed therapy, patients with lymphoma are in need of a supportive measures. In the second part of this guideline, the prevention and treatment of tumour lysis dyndrome, cardiac support and physiotherapy are discussed.
- Published
- 2022
7. BHS guidelines on supportive care in lymphoma : Part 2
- Author
-
Janssens, M, Saelvels, K, Vergote, V, Lemmens, J, Bailly, S, Janssens, A, Snauwaert, S, André, Marc, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie
- Subjects
cardiac support ,supportive care ,physiotherapy ,tumour lysis syndrome - Abstract
Besides disease-directed therapy, patients with lymphoma are in need of a supportive measures. In the second part of this guideline, the prevention and treatment of tumour lysis dyndrome, cardiac support and physiotherapy are discussed.
- Published
- 2022
8. DIAGNOSIS AND TREATMENT OF PERIPHERAL T-CELL LYMPHOMAS: UPDATE RECOMMENDATIONS OF THE BELGIAN HEMATOLOGY SOCIETY (BHS)
- Author
-
Wolfromm, A, Bailly, S, Van Den Neste, E, André, Marc, Saevels, K, Antoine Poirel, H, Tousseyn, T, Van Hende, V, Snauwaert, S, Janssens, A, Jacquy, C, Bonnet, C, UCL - (MGD) Service d'hématologie, and UCL - SSS/IREC/MONT - Pôle Mont Godinne
- Subjects
autologous stem cell transplantation ,BV-CHP ,peripheral T-cell lymphoma not otherwise specified ,Anaplastic large-cell lymphoma ,peripheral T-cell lymphoma ,angioimmunoblastic T-cell lymphoma - Abstract
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive diseases associated with poor outcomes. Recent progress in understanding of the biology and pathogenesis based on molecular profiling and next-generation sequencing has led to the introduction of new provisional entities in the World Health Organization (WHO) classification system of 2017 and to the emergence of new drugs.1 Previous Belgian guidelines were published in 2013.2 This review will discuss the diagnosis, work-up and treatment of PTCL including these advances as well as the limitation of the availability of drugs according to the Belgian reimbursement rules.
- Published
- 2022
9. In vitro generation of mature, naive antigen-specific CD8+ T cells with a single T-cell receptor by agonist selection
- Author
-
Snauwaert, S, Verstichel, G, Bonte, S, Goetgeluk, G, Vanhee, S, Van Caeneghem, Y, De Mulder, K, Heirman, C, Stauss, H, Heemskerk, M H M, Taghon, T, Leclercq, G, Plum, J, Langerak, A W, Thielemans, K, Kerre, T, and Vandekerckhove, B
- Published
- 2014
- Full Text
- View/download PDF
10. EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3‐YEAR FOLLOW‐UP
- Author
-
Janssens, A, primary, Snauwaert, S, additional, Bron, D, additional, Berneman, Z, additional, Offner, F, additional, Van Bogaert, C, additional, De Beleyr, B, additional, Smet, A, additional, Nielsen, L, additional, Wapenaar, R, additional, and André, M, additional
- Published
- 2021
- Full Text
- View/download PDF
11. How to treat classical Hodgkin's lymphoma in older patients : Belgian expert opinion
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Snauwaert, S, Van Hende, V, Janssens, A, André, Marc, Van Hecke, S, Van Den Neste, E, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Snauwaert, S, Van Hende, V, Janssens, A, André, Marc, Van Hecke, S, and Van Den Neste, E
- Abstract
Classical Hodgkin's lymphoma (cHL) is a rather rare disease with an incidence of 2-3/100,000 per year and typically presents in patients at the age of 20-30. lt is however well known that a second peak occurs at the age of 60-65 years.1 Nowadays Hodgkin is a curable disease for most of the younger patients but treatment is more difficult and less successful in the aider patient population. ln this review, we want to summarise the possibilities for the treatment of cHL patients above 60 years, with a focus on evidence from the raher rarely available clinical trials. We also look at future treatments . ln this article we will use the term 'aider.patients' for patients of 60 years and older at diagnosis. We will make a distinction between fit patients older than 60 years and frail or vulnerable patients (so called elderly).
- Published
- 2021
12. Notch induces human T-cell receptor γδ+ thymocytes to differentiate along a parallel, highly proliferative and bipotent CD4 CD8 double-positive pathway
- Author
-
Van Coppernolle, S, Vanhee, S, Verstichel, G, Snauwaert, S, van der Spek, A, Velghe, I, Sinnesael, M, Heemskerk, M H, Taghon, T, Leclercq, G, Plum, J, Langerak, A W, Kerre, T, and Vandekerckhove, B
- Published
- 2012
- Full Text
- View/download PDF
13. In vitro generation of mature, naive antigen-specific CD8 + T cells with a single T-cell receptor by agonist selection
- Author
-
Snauwaert, S, Verstichel, G, Bonte, S, Goetgeluk, G, Vanhee, S, Van Caeneghem, Y, De Mulder, K, Heirman, C, Stauss, H, Heemskerk, M HM, Taghon, T, Leclercq, G, Plum, J, Langerak, A W, Thielemans, K, Kerre, T, and Vandekerckhove, B
- Published
- 2014
- Full Text
- View/download PDF
14. In vitro generation of antigen-specific T-cells from CD34+ haematopoietic progenitor cells: a new and promising immunotherapeutic strategy: O181
- Author
-
Snauwaert, S., Van Coppernolle, S., Verstichel, G., Goetgeluk, G., Van Caeneghem, Y., Vanhee, S., Velghe, I., Plum, J., and Kerre, T.
- Published
- 2013
15. Double positive and double negative TCR γ delta+ cells independently generate mature functional TCR γ delta + cells in the human thymus: P1044
- Author
-
Van Coppernolle, S., Vanhee, S., Verstichel, G., Snauwaert, S., Velghe, I., Sinnesael, M., van der Spek, A., Taghon, T., Leclercq, G., Plum, J., Langerak, A., Kerre, T., and Vandekerckhove, B.
- Published
- 2011
16. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY
- Author
-
Cottereau, A., primary, Vercellino, L., additional, Casasnovas, O., additional, Tilly, H., additional, Feugier, P., additional, Fruchart, C., additional, Roulin, L., additional, Oberic, L., additional, Pica, G., additional, Ribrag, V., additional, Abraham, J., additional, Simon, M., additional, Gonzalez, H., additional, Bouabdallah, R., additional, Fitoussi, O., additional, Sebban, C., additional, Lopez, A., additional, Macro, M., additional, Sahnes, L., additional, Morschhauser, F., additional, Trotman, J., additional, Corront, B., additional, Choufi, B., additional, Snauwaert, S., additional, Godmer, P., additional, Copie-Bergman, C., additional, Briere, J., additional, Salles, G., additional, Gaulard, P., additional, Meignan, M., additional, and Thieblemont, C., additional
- Published
- 2019
- Full Text
- View/download PDF
17. PF384 EFFECTIVENESS AND SAFETY OF IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN ROUTINE CLINICAL PRACTICE: INTERIM ANALYSIS (IA) OF THE BELGIAN IBRUTINIB REAL-WORLD DATA (BIRD) STUDY
- Author
-
Janssens, A., primary, André, M., additional, Berneman, Z., additional, Snauwaert, S., additional, De Beleyr, B., additional, Smet, A., additional, Van Bogaert, C., additional, Wapenaar, R., additional, and Bron, D., additional
- Published
- 2019
- Full Text
- View/download PDF
18. PF204 TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT
- Author
-
Depreter, B., primary, Weening, K., additional, Vandepoele, K., additional, Essand, M., additional, De Moerloose, B., additional, Themeli, M., additional, Cloos, J., additional, Hanekamp, D., additional, Moors, I., additional, D’hont, I., additional, Denys, B., additional, Uyttebroeck, A., additional, Van Damme, A., additional, Dedeken, L., additional, Snauwaert, S., additional, Goetgeluk, G., additional, De Munter, S., additional, Kerre, T., additional, Vandekerckhove, B., additional, Lammens, T., additional, and Philippé, J., additional
- Published
- 2019
- Full Text
- View/download PDF
19. FUNCTIONAL EVALUATION OF T-CELLS GENERATED FROM WT1-TCR TRANSDUCED HUMAN HEMATOPOIETIC STEM CELLS USING THE OP9-DL1 COCULTURE SYSTEM
- Author
-
Bonte, S., Snauwaert, S., Goetgeluk, G., Heemskerk, M., Stauss, H., Vandekerckhove, B., and Kerre, T.
- Published
- 2014
20. Combination of pixantrone with rituximab, ifosfamide and etoposide in relapsed/refractory aggressive non‐Hodgkin lymphoma. Results from a phase II LYSA study (PIVeR).
- Author
-
Fornecker, L., Delwail, V., Thieblemont, C., Ghesquieres, H., Bouabdallah, K., Tilly, H., Le Calloch, R., Morschhauser, F., Costello, R., Slama, B., Gyan, E., Chauchet, A., Ngirabacu, M., Durot, E., Choquet, S., Capdupuy, C., Le Goff, M., Voillat, L., Snauwaert, S., and Amorim, S.
- Subjects
NON-Hodgkin's lymphoma ,IFOSFAMIDE ,RITUXIMAB ,DIFFUSE large B-cell lymphomas - Abstract
R/R disease was defined as follows: (1) autologous stem-cell transplantation (ASCT) eligible patients who failed to achieve a CR after at least one salvage therapy, (2) patients in first relapse after ASCT or (3) patients not eligible for ASCT who failed to achieve a CR after at least one prior treatment. Results from a phase II LYSA study (PIVeR) B Introduction: b The prognosis of patients with relapsed/refractory aggressive non-hodgkin lymphoma (R/R aNHL) remains poor with conventional immunochemotherapies. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
21. 79 Intravenous colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis (CF) patients
- Author
-
Schelstraete, P., primary, Claus, B., additional, Snauwaert, S., additional, Haerynck, F., additional, Van Daele, S., additional, and De Baets, F., additional
- Published
- 2014
- Full Text
- View/download PDF
22. In vitro generation of mature, naive antigen-specific CD8+ T cells with a single T-cell receptor by agonist selection
- Author
-
Snauwaert, S, primary, Verstichel, G, additional, Bonte, S, additional, Goetgeluk, G, additional, Vanhee, S, additional, Van Caeneghem, Y, additional, De Mulder, K, additional, Heirman, C, additional, Stauss, H, additional, Heemskerk, M H M, additional, Taghon, T, additional, Leclercq, G, additional, Plum, J, additional, Langerak, A W, additional, Thielemans, K, additional, Kerre, T, additional, and Vandekerckhove, B, additional
- Published
- 2013
- Full Text
- View/download PDF
23. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia
- Author
-
Snauwaert, S., primary, Vanhee, S., additional, Goetgeluk, G., additional, Verstichel, G., additional, Van Caeneghem, Y., additional, Velghe, I., additional, Philippe, J., additional, Berneman, Z. N., additional, Plum, J., additional, Taghon, T., additional, Leclercq, G., additional, Thielemans, K., additional, Kerre, T., additional, and Vandekerckhove, B., additional
- Published
- 2012
- Full Text
- View/download PDF
24. Notch induces human T-cell receptor γδ+ thymocytes to differentiate along a parallel, highly proliferative and bipotent CD4 CD8 double-positive pathway
- Author
-
Van Coppernolle, S, primary, Vanhee, S, additional, Verstichel, G, additional, Snauwaert, S, additional, van der Spek, A, additional, Velghe, I, additional, Sinnesael, M, additional, Heemskerk, M H, additional, Taghon, T, additional, Leclercq, G, additional, Plum, J, additional, Langerak, A W, additional, Kerre, T, additional, and Vandekerckhove, B, additional
- Published
- 2011
- Full Text
- View/download PDF
25. In vitro generation of mature, naive antigen-specific CD8+ T cells with a single T-cell receptor by agonist selection.
- Author
-
Snauwaert, S, Verstichel, G, Bonte, S, Goetgeluk, G, Vanhee, S, Van Caeneghem, Y, De Mulder, K, Heirman, C, Stauss, H, Heemskerk, M H M, Taghon, T, Leclercq, G, Plum, J, Langerak, A W, Thielemans, K, Kerre, T, and Vandekerckhove, B
- Subjects
- *
T cells , *T-cell receptor genes , *CELL cycle , *FUNCTIONAL analysis , *PEPTIDES - Abstract
Peripheral blood T cells transduced with a tumor-specific T-cell receptor (TCR) face problems of auto-reactivity and lack of efficacy caused by cross-pairing of exogenous and endogenous TCR chains, as well as short term in vivo survival due to activation and growth factor-induced differentiation. We here studied an alternative strategy for the efficient generation of naive CD8+ T cells with a single TCR. TCR-transduced human postnatal thymus-derived and adult mobilized blood-derived hematopoietic progenitor cells (HPCs) were differentiated to CD4+CD8+ double-positive T cells using OP9-Delta-like 1 (OP9-DL1) cultures. Addition of the agonist peptide induced double positive cells to cross-present the peptide, leading, in the absence of co-stimulation, to cell cycle arrest and differentiation into mature CD8+ T cells. Comprehensive phenotypic, molecular and functional analysis revealed the generation of naive and resting CD8+ T cells through a process similar to thymic positive selection. These mature T cells show a near complete inhibition of endogenous TCRA and TCRB rearrangements and express high levels of the introduced multimer-reactive TCR. Upon activation, specific cytokine production and efficient killing of tumor cells were induced. Using this strategy, large numbers of high-avidity tumor-specific naive T cells can be generated from readily available HPCs without TCR chain cross-pairing. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
26. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
- Author
-
Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, and Lemonnier F
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Administration, Oral, Bendamustine Hydrochloride therapeutic use, Bendamustine Hydrochloride administration & dosage, Bendamustine Hydrochloride adverse effects, Gemcitabine, Lymphoma, Follicular drug therapy, Lymphoma, Follicular mortality, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Depsipeptides therapeutic use, Depsipeptides adverse effects, Depsipeptides administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antimetabolites, Antineoplastic therapeutic use, Antimetabolites, Antineoplastic adverse effects, Antimetabolites, Antineoplastic administration & dosage, Aged, 80 and over, Azacitidine therapeutic use, Azacitidine adverse effects, Azacitidine administration & dosage
- Abstract
Background: Follicular helper T-cell lymphomas (TFHL) harbour frequent alterations in genes that regulate DNA methylation. Preliminary reports suggest that treatment with 5-azacitidine has clinical activity in patients with relapsed or refractory TFHL. We aimed to compare the oral form of azacitidine with investigator's choice standard therapy (ICT; ie, gemcitabine, bendamustine, or romidepsin) in patients with relapsed or refractory TFHL., Methods: Patients older than 18 years with relapsed or refractory TFHL (angioimmunoblastic T-cell lymphoma, follicular lymphoma, or nodal T-cell lymphoma with phenotype, ie, positive with two or more markers among CD10, BCL6, CXCL13, PD1, or ICOS) based on the 2017 WHO classification of haematological neoplasms, with an Eastern Cooperative Oncology Group performance status score of 0-3, were recruited in university hospitals from five European countries and from Japan. Patients were randomly assigned 1:1 to treatment with either azacitidine given at a dose of 300 mg once a day (200 mg in Japanese patients) for 14 days in a 28-day cycle or gemcitabine, bendamustine, or romidepsin according to the investigator's choice. Random assignment was stratified by the number of previous lines of therapy and by the presence of previous or concomitant myeloid malignancy. The primary endpoint was investigator-assessed progression-free survival, presented in the intention-to-treat population. This Article is the final analysis of this trial, registered at ClinicalTrials.gov (Europe NCT03593018 and Japan NCT03703375)., Findings: 86 patients (median age 69 years [IQR 62-76], 50 patients were male, 36 were female) were enrolled between Nov 9, 2018, to Feb 22, 2021; 42 in the azacitidine group and 44 in the ICT group. With a median follow-up of 27·4 months (IQR 20·2-32·9), the median progression-free survival was 5·6 months (95% CI 2·7 -8·1) in the azacitidine group versus 2·8 months (1·9-4·8) in the ICT group (hazard ratio of 0·63 (95% CI 0·38-1·07); 1-sided p=0·042). Grade 3-4 adverse events were reported in 32 (76%) of 42 patients in the azacitidine group versus 42 (98%) of 43 patients in the ICT group. The most adverse grade 3 or worse adverse events were haematological (28 [67%] of 42 patients vs 40 [93%] of 43 patients), infection (8 [19%] and 14 [33%]), and gastrointestinal (5 [12%] vs 1 [2%] for azacitidine and ICT, respectively). There were two treatment-related deaths in the azacitidine group (one endocarditis and one candidiasis) and three in the ICT group (one heart failure, one COVID-19, and one cause unknown)., Interpretation: Although the pre-specified primary outcome of the trial was not met, the favourable safety profile suggests that azacitidine could add to the treatment options in these difficult to treat diseases especially in combination with other drugs. Trials with combination are in preparation in a platform trial., Funding: Bristol-Myers Squibb., Translation: For the French translation of the abstract see Supplementary Materials section., Competing Interests: Declaration of interests EB reports receiving research funding from Amgen and Bristol-Myers Squibb (BMS); honoraria from Kite, Gilead, Novartis, Roche, Incyte, Miltenyi Biotech, Takeda, and Sanofi; and participation on an advisory committee for Roche, Gilead, ADC Therapeutics, Takeda, Novartis, and Incyte. FM reports receiving consultancy fees from Roche, Gilead, and AbbVie and participation on advisory committees for Roche, Gilead, Novartis, BMS, AbbVie, Genmab, Miltenyi, Allogene Therapeutics, AstraZeneca, and Janssen. GC reports receiving honoraria from Gilead, Novartis, Mylteni, Sanofi, AbbVie, Takeda, Roche, Janssen, Roche, Celgene, Novartis and participation on advisory committees for MabQi, Ownards Therapeutics, AbbVie, Roche, and BMS. NF reports receiving consultancy fees from AstraZeneca, AbbVie, Eli Lilly, HUYA, and Novartis; research funding from Bayer, BMS, Chugai Pharma, Celgene, Genmab, and Incyte; honoraria from AstraZeneca, BMS, Chugai Pharma, Dainippon Sumitomo, Eisai, Janssen, Kyowa Kirin, Nippon Shinyaku, Novartis, Ono, Sanofi, Symbio, Takeda, and Celgene. R-OC reports receiving honoraria from Roche, Takeda, Merck, BMS, Gilead and Kite, AbbVie, ADC Therapeutics, and Incyte; research funding from Takeda and Gilead and Kite; honoraria from Roche, Takeda, Merck, BMS, Gilead and Kite, AbbVie, ADC Therapeutics, Incyte and AstraZeneca; and participation on advisory committees for Roche, Takeda, Merck, BMS, Gilead and Kite, ADC Therapeutics, Janssen, and Incyte. CPF reports receiving consultancy fees from AbbVie, AstraZeneca, Atarabio, Celgene and BMS, GenMab, Gilead and Kite, Incyte, Janssen, Morphosys, Ono Pharmaceutical, Roche, and Takeda; research funding from BeiGene; and speaker bureau fees from Celgene and BMS, Gilead and Kite, Incyte, Janssen, Roche, and Takeda; and travel support from Roche. FAd’A reports receiving research funding from Servier and Nordic Nanovector. PBS reports receiving consultancy fees from Amgen, Roche, Janssen, Gilead, Incyte, Morphosys, CTI Biopharma, BMS, Celegene, AbbVie, Takeda, BMS, Beigene, and Lilly; research funding from Roche; and honoraria from Amgen, Roche, Janssen, Gilead, Incyte, Morphosys, CTI Biopharma, BMS, Celegene, AbbVie, Takeda, BMS, Beigene, and Lilly. AG and MN are current employees and stock option holders at BMS. L-MF reports receiving honoraria from Roche, AbbVie, Janssen, and AstraZeneca. M-HD-L reports receiving research funding from Roche and Celgene; honoraria from Gilead and Amgen and travel support from Mundipharma. LdL reports receiving consultancy fees from Lunaphore Technologies and Bayer and honoraria from Novartis. PG reports receiving consultancy fees from Takeda; research funding from Takeda, Innate Pharma, Alderan, and Sanofi; and honoraria from Takeda Gilead. KT reports receiving consultancy fees from Ono Pharma, Meiji Seika Pharma, Yakuruto, Solasia Pharma, Meiji Seika Pharma, and HUYABIO; research funding from Kyowa-hakko and Kirin, Meiji Seika Pharma, BMS, Byer, Daiich-Sankyo, HUYABIO, and Regeneron Pharmaceuticals; and honoraria from Chugai Pharma, Eizai, and Meiji Seika Pharma. FL reports receiving honoraria from Kiowa, Miltenyi, and BMS; research funding from Roche and BMS; and travel support from Roche and Gilead. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
27. Epidemiological characteristics and outcome of viral respiratory tract infections in the first year after allogeneic hematopoietic cell transplantation.
- Author
-
Van Praet JT, Huysman A, De Knijf E, De Buyser S, Snauwaert S, Van Droogenbroeck J, Lodewyck T, Schauwvlieghe A, Selleslag D, and Reynders M
- Abstract
Adverse outcomes of viral respiratory tract infections (RTI) have been reported in recipients of allogeneic hematopoietic cell transplantation. Using a laboratory-developed multiparameter PCR in a consecutive series of 242 patients, we found the highest incidence of viral RTI in the pre-engraftment phase. The occurrence of multiple episodes of viral RTI or viral pneumonia was significantly associated with a higher hazard of non-relapse mortality in the first year after transplantation. We observed a 90-day mortality of 19.7% after viral RTI, which was significantly different between patient groups stratified according to the ISI score., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
28. Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?
- Author
-
Blomme S, De Paepe P, Devos H, Emmerechts J, Snauwaert S, and Cauwelier B
- Subjects
- Humans, Gene Rearrangement, In Situ Hybridization, Fluorescence, Prognosis, Proto-Oncogene Proteins c-bcl-6 genetics, Proto-Oncogene Proteins c-myc genetics, Retrospective Studies, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse pathology, Proto-Oncogene Proteins c-bcl-2 genetics
- Abstract
High-grade B-cell lymphoma (HGBL)/diffuse large B-cell lymphoma (DLBCL) with rearrangements (R) in MYC and BCL2 and/or BCL6 are correlated with poor prognosis. Little is known about the impact of other genetic alterations (gain (G) or amplification (A)) of these genes. The aim of the study was to investigate whether we can identify new prognostic subgroups. Fluorescence in situ hybridization (FISH) results from 169 HGBL/DLBCL were retrospectively categorized into: (1) concurrent MYC-R and BCL2-R and/or BCL6-R-samples with MYC-R and BCL2-R (+/- BCL6-R); n = 21, and HGBL/DLBCL with MYC-R and BCL6-R; n = 11; (2) concurrent R and G/A in MYC and BCL2 and/or BCL6 called "alternative HGBL/DLBCL"-samples with (n = 16) or without (n = 6) BCL2 involvement; (3) BCL2 and/or BCL6 alterations without MYC involvement (n = 35); (4) concurrent G/A in MYC and BCL2 and/or BCL6 without R (n = 25); and (5) "No alterations" (n = 55). Patients with HGBL/DLBCL-MYC/BCL2 and "alternative" HGBL/DLBCL (with BCL2 involvement) had significantly worse survival rates compared to the "no alterations" group. G/A of these genes in the absence of rearrangements did not show any prognostic significance. HGBL/DLBCL with MYC-R and BCL6-R without BCL2 involvement showed a better survival rate compared to HGBL/DLBCL-MYC/BCL2. According to immunohistochemistry, "double/triple" expression (DEL/TEL) did not show a significantly worse outcome compared to absent DEL/TEL. This study highlights the continued value of FISH assessment of MYC, BCL2, and BCL6 in the initial evaluation of HGBL/DLBCL with different survival rates between several genetic subgroups., (© 2023 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
29. Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity?
- Author
-
Vets J, Marcelis L, Schepers C, Dorreman Y, Verbeek S, Vanwalleghem L, Gieraerts K, Meylaerts L, Lesaffer J, Devos H, Put N, Snauwaert S, De Paepe P, and Tousseyn T
- Subjects
- Humans, Female, Herpesvirus 4, Human, Ki-1 Antigen, Breast Implants adverse effects, HIV Infections, Breast Neoplasms pathology, Lymphoma, Large-Cell, Anaplastic diagnosis, Lymphoma, Large-Cell, Anaplastic etiology, Lymphoma, Large-Cell, Anaplastic pathology, Lymphoma, Large B-Cell, Diffuse diagnosis
- Abstract
Breast-implant associated (BIA) lymphoma is an infrequent type of cancer occurring in the fluid and fibrous capsule around a textured breast implant. Recently, both the 2022 WHO 5th edition classification of Haematological tumours (WHO HAEM5) and 2022 International Consensus Classification of Mature Lymphoid Neoplasms (22ICC), recognized breast implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) as a definitive entity, defined as a mature CD30-positive T-cell lymphoma, confined by a fibrous capsule, in a breast implant setting. Only few B-cell lymphomas have been reported in the literature to be associated with breast implants. Here we report two EBV-positive Diffuse Large B-cell lymphomas (EBV + DLBCL) in relation to a breast implant, both expressing CD30 as well as EBV latency type 3. Both lesions were considered as DLBCL associated with chronic inflammation (CI-DLBCL), but one presented as a 7 cm solid mass, while the other presented as a fibrin-associated DLBCL (FA-DLBCL) in an HIV patient. Clinically, both are in complete remission 6 months or longer after capsulectomy and graft removal, without additional chemotherapy.Such cases, characterized by large CD30-positive cells, can easily be misdiagnosed as BIA-ALCL if the cell of origin is not further established. Therefore, a diagnostic panel including lineage-specific B-and T-cell markers and EBER in situ hybridization is essential to recognize this rare entity, to understand lymphomagenesis, to predict outcome and to define clinical approach., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
30. Infectious diarrhea after allogeneic hematopoietic cell transplantation assessed by a multiplex polymerase chain reaction assay.
- Author
-
Van Praet JT, Huysman A, De Knijf E, De Buyser S, Snauwaert S, Van Droogenbroeck J, Lodewyck T, Schauwvlieghe A, Selleslag D, and Reynders M
- Subjects
- Humans, Multiplex Polymerase Chain Reaction, Retrospective Studies, Risk Factors, Diarrhea epidemiology, Diarrhea etiology, Hematopoietic Stem Cell Transplantation adverse effects, Cross Infection etiology
- Abstract
Objectives: To determine the incidence of infectious diarrhea after allogeneic hematopoietic cell transplantation (HCT) using a multiplex polymerase chain reaction assay and assess risk factors for developing infectious diarrhea., Methods: This was a single-center retrospective study of 140 consecutive allogeneic HCT recipients. Infectious diarrhea was assessed using a laboratory-developed multiplex polymerase chain reaction the first year after transplantation., Results: The incidence rate of infectious diarrhea episodes was 47 per 100 person-years, with the highest rate observed in the pre-engraftment phase. Most episodes were seen as nosocomial infections (38%) and most affected patients (82%) had only one episode of infectious diarrhea. The cumulative incidence of at least one episode of infectious diarrhea was 32% after 1 year. Nonrelapse mortality was higher in transplant recipients with at least one episode of infectious diarrhea (hazard ratio (HR) 2.02, 95% CI = 1.07-3.80). The most frequently observed pathogens were Clostridium difficile, adenovirus, Enteropathogenic Escherichia coli, and Campylobacter jejuni. Patients with acute lower gastrointestinal graft-vs-host disease stage 3 or 4 (HR 3.68, 95% CI = 1.57-8.63) conferred a higher risk for a first infectious diarrhea episode., Conclusion: Infectious diarrhea after allogeneic HCT was seen in about one-third of the patients, mostly as nosocomial infection in the pre-engraftment phase., Competing Interests: Declarations of competing interest The authors have no competing interests to declare., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
31. Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.
- Author
-
Janssens A, Berneman ZN, Offner F, Snauwaert S, Mineur P, Vanstraelen G, Meers S, Spoormans I, Bron D, Vande Broek I, Van Bogaert C, De Beleyr B, Smet A, Nielsen L, Wapenaar R, and André M
- Abstract
The multicenter observational BiRD study investigated the real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM) in Belgium. This interim analysis reports results for patients with CLL, with a median follow-up of 34 months. Overall, patients had predominantly relapsed/refractory disease (73%) and were elderly (median age 72 years) with high-risk features such as del17p and/or TP53 mutations (59%). Patients were included either prospectively or retrospectively, and the total patient population effectiveness results were adjusted with left truncation. In the effectiveness population (N = 221: prospective, n = 71; retrospective, n = 150), the overall response rate was 90.0%. Median progression-free survival was 38.3 months (prospective, not estimable; retrospective, 51.5 months) and median overall survival was not yet estimable in the total, prospective and retrospective groups. Treatment-emergent adverse events (TEAEs) for the prospective and retrospective groups are reported separately. Any-grade TEAEs of interest in the prospective/retrospective groups included infections (67.1%/60.1%), diarrhea (20.5%/10.5%), hypertension (16.4%/9.8%) and atrial fibrillation (12.3%/7.2%). Major bleeding was reported in 5.5%/3.3% of prospective/retrospective patients, with little difference observed between those receiving versus not receiving antithrombotic treatment. Discontinuations due to toxicity were reported in 10.5% of patients. Results from this interim analysis show treatment with ibrutinib to be effective and tolerable, with no new safety signals observed. Future analyses will report on longer-term follow-up., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
32. The choice between deceased and living donor kidney transplantation in children and adolescents: a multicentric cross-sectional study.
- Author
-
Laure D, Lore W, Ann R, Koen VH, Katty VC, Johan VW, Evelien S, Elena L, Noël K, and Agnieszka P
- Subjects
- Adolescent, Child, Cross-Sectional Studies, Female, Graft Survival, Humans, Kidney, Living Donors, Male, Kidney Transplantation, Renal Insufficiency, Chronic
- Abstract
Introduction: The aim of our study was to evaluate the factors influencing the choice between a deceased donor (DD) and living donor kidney transplantation (LD KT) for children and adolescents with chronic kidney disease (CKD) from the perspective of parents and physicians., Methods: Patients with CKD stages 4 and 5 at the University Hospitals of Ghent, Leuven and Antwerp were included. Between February 2019 and March 2020, the corresponding questionnaires were distributed among parents and physicians in order to evaluate the potential differences between the medical recommendation and parental choice., Results: Twenty-eight patients (median age 11 yr, range 2-19 yr), 10 girls and 18 boys were included. Three patients had undergone kidney transplantation in the past. Parents of 13 children opted for DD and 13 LD, and in two cases, there was no preference. Physicians recommended DD in 14 cases and LD in 14 cases. Parental choice corresponded with physician's recommendation in 22 cases. Parental reasons for choosing DD were medical (n = 7), socio-economic (n = 1), combination of both (n = 1) or no reason (n = 4). Pediatric nephrologists advised against LD for medical (n = 6) or socio-economic (n = 6) reasons or a combination of both (n = 2)., Conclusion: In our cohort, the treating physicians regarded the family's socio-economic factors more important for not actively promoting LD than the parents. A better understanding and communication regarding perceived socio-economic hurdles between caretakers and families might contribute to a higher incidence of living kidney donation in Belgium.
- Published
- 2022
- Full Text
- View/download PDF
33. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
- Author
-
Bachy E, Houot R, Feugier P, Bouabdallah K, Bouabdallah R, Virelizier EN, Maerevoet M, Fruchart C, Snauwaert S, Le Gouill S, Marolleau JP, Molina L, Moluçon-Chabrot C, Thieblemont C, Tilly H, Bijou F, Haioun C, Van den Neste E, Fabiani B, Meignan M, Cartron G, Salles G, Casasnovas O, and Morschhauser F
- Subjects
- Adolescent, Adult, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols adverse effects, Humans, Lenalidomide therapeutic use, Treatment Outcome, Lymphoma, Follicular pathology, Neutropenia drug therapy
- Abstract
Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously untreated patients with advanced follicular lymphoma (FL). Eligible patients aged ≥18 years had an Eastern Cooperative Oncology Group performance status ≤2 and high-tumor burden, grade 1 to 3a FL. Induction treatment was obinutuzumab (1000 mg IV, days 8, 15, and 22, cycle 1; day 1, cycles 2-6) plus lenalidomide (20 mg/d, days 1-21, cycle 1; days 2-22, cycles 2-6) for six 28-day cycles. Maintenance included obinutuzumab (1000 mg every 2 cycles) plus lenalidomide (10 mg, days 2-22) for ≤12 cycles (year 1) followed by obinutuzumab (1000 mg every 56 days) for 6 cycles (year 2). The primary end point was complete response rate (CRR) after induction per the 1999 International Working Group criteria. From October 2015 to February 2017, a total of 100 patients were enrolled. CRR after induction was 47%, and the overall response rate (ORR) was 92%. Post hoc analyses per the 2014 Lugano classification, including patients with missing bone marrow assessments, identified an additional 13 patients fulfilling CRR criteria, resulting in a complete metabolic response of 80% and an ORR of 94%. At a median follow-up of 3.7 years, 3-year progression-free survival and overall survival were 82% and 94%, respectively. The most common adverse event was neutropenia (48% any grade; 47% grade ≥3). Only 2% of patients presented with febrile neutropenia; others were mainly grade ≤2. No other specific grade ≥3 toxicity occurred at a frequency >3%. Overall, these results showed promising clinical efficacy for the chemotherapy-free GALEN backbone in previously untreated patients with high tumor burden FL. Except for neutropenia, the safety profile of the combination is remarkable. The study was registered at clinicaltrials.gov as #NCT01582776., (© 2022 by The American Society of Hematology.)
- Published
- 2022
- Full Text
- View/download PDF
34. TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.
- Author
-
Depreter B, Weening KE, Vandepoele K, Essand M, De Moerloose B, Themeli M, Cloos J, Hanekamp D, Moors I, D'hont I, Denys B, Uyttebroeck A, Van Damme A, Dedeken L, Snauwaert S, Goetgeluk G, De Munter S, Kerre T, Vandekerckhove B, Lammens T, and Philippé J
- Subjects
- Adult, Child, Humans, Immunotherapy, Male, Nuclear Proteins, Receptors, Antigen, T-Cell, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute therapy
- Abstract
Immunotherapeutic strategies targeting the rare leukemic stem cell compartment might provide salvage to the high relapse rates currently observed in acute myeloid leukemia (AML). We applied gene expression profiling for comparison of leukemic blasts and leukemic stem cells with their normal counterparts. Here, we show that the T-cell receptor γ chain alternate reading frame protein (TARP) is over-expressed in de novo pediatric (n=13) and adult (n=17) AML sorted leukemic stem cells and blasts compared to hematopoietic stem cells and normal myeloblasts (15 healthy controls). Moreover, TARP expression was significantly associated with a fms-like tyrosine kinase receptor-3 internal tandem duplication in pediatric AML. TARP overexpression was confirmed in AML cell lines (n=9), and was found to be absent in B-cell acute lymphocytic leukemia (n=5) and chronic myeloid leukemia (n=1). Sequencing revealed that both a classical TARP transcript, as described in breast and prostate adenocarcinoma, and an AML-specific alternative TARP transcript, were present. Protein expression levels mostly matched transcript levels. TARP was shown to reside in the cytoplasmic compartment and showed sporadic endoplasmic reticulum co-localization. TARP-T-cell receptor engineered cytotoxic T-cells in vitro killed AML cell lines and patient leukemic cells co-expressing TARP and HLA-A*0201. In conclusion, TARP qualifies as a relevant target for immunotherapeutic T-cell therapy in AML., (Copyright© 2020 Ferrata Storti Foundation.)
- Published
- 2020
- Full Text
- View/download PDF
35. High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
- Author
-
Vercellino L, Cottereau AS, Casasnovas O, Tilly H, Feugier P, Chartier L, Fruchart C, Roulin L, Oberic L, Pica GM, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O, Sebban C, López-Guillermo A, Sanhes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Briere J, Salles G, Gaulard P, Meignan M, and Thieblemont C
- Subjects
- Aged, Aged, 80 and over, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Female, Humans, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse metabolism, Male, Middle Aged, Prednisone therapeutic use, Prognosis, Rituximab therapeutic use, Vincristine therapeutic use, Angiogenesis Inhibitors therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lenalidomide therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse pathology, Tumor Burden drug effects
- Abstract
Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts survival of DLBCL patients. We analyzed the prognostic impact of TMTV and prognostic indices in DLBCL patients, aged 60 to 80 years, from the phase 3 REMARC study that randomized responding patients to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) into maintenance lenalidomide or placebo. TMTV was computed on baseline positron emission tomography/computed tomography using the 41% maximum standardized uptake value method; the optimal TMTV cutoff for progression-free (PFS) and overall survival (OS) was determined and confirmed by a training validation method. There were 301 out of 650 evaluable patients, including 192 patients classified as germinal center B-cell-like (GCB)/non-GCB and MYC/BCL2 expressor. Median baseline TMTV was 238 cm3; optimal TMTV cutoff was 220 cm3. Patients with high vs low TMTV showed worse/higher Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, stage III or IV disease, >1 extranodal site, elevated lactate dehydrogenase, International Prognostic Index (IPI) 3-5, and age-adjusted IPI 2-3. High vs low TMTV significantly impacted PFS and OS, independent of maintenance treatment. Although the GCB/non-GCB profile and MYC expression did not correlate with TMTV/survival, BCL2 >70% impacted PFS and could be stratified by TMTV. Multivariate analysis identified baseline TMTV and ECOG PS as independently associated with PFS and OS. Even in responding patients, after R-CHOP, high baseline TMTV was a strong prognosticator of inferior PFS and OS. Moreover, TMTV combined with ECOG PS may identify an ultra-risk DLBCL population. This trial was registered at www.clinicaltrials.gov as #NCT01122472., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
36. Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
- Author
-
Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, van Eygen K, Obéric L, Bouabdallah R, Pica GM, Nicolas-Virezelier E, Abraham J, Fitoussi O, Snauwaert S, Eisenmann JC, Lionne-Huyghe P, Bron D, Tricot S, Deeren D, Gonzalez H, Costello R, Le Du K, da Silva MG, Grosicki S, Trotman J, Catalano J, Caballero D, Greil R, Cohen AM, Gaulard P, Roulin L, Takeshita K, Casadebaig ML, Tilly H, and Coiffier B
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Doxorubicin administration & dosage, Doxorubicin adverse effects, Female, Humans, Lenalidomide adverse effects, Male, Middle Aged, Prednisone administration & dosage, Prednisone adverse effects, Rituximab administration & dosage, Rituximab adverse effects, Vincristine administration & dosage, Vincristine adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Lenalidomide administration & dosage, Lymphoma, Large B-Cell, Diffuse drug therapy, Maintenance Chemotherapy, Quality of Life
- Abstract
Lenalidomide maintenance therapy prolonged progression-free survival (PFS) versus placebo in elderly patients with diffuse large B-cell lymphoma (DLBCL) responding to induction chemotherapy in the phase 3 REMARC study. This subpopulation analysis assessed the impact of lenalidomide maintenance and treatment-emergent adverse events (TEAEs) on health-related quality of life (HRQOL). Global health status (GHS), and physical functioning and fatigue subscales were evaluated in patients who completed the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire-C30 v3.0. The impact of TEAEs classified post hoc as subjective (patients can feel) or observable (only measurable by physicians) on dose reductions and discontinuations was assessed. Among 457 patients (lenalidomide, n = 229; placebo, n = 228), mean (standard deviation) GHS was similar between treatment arms [68·2 (20·7) Versus 72·0 (17·8)] at randomisation and remained similar during maintenance. Patients receiving lenalidomide experienced no meaningful changes in GHS, physical functioning, or fatigue. Observable TEAEs were more common (81·1% Versus 66·3%) and more likely to lead to dose reductions, than subjective TEAEs in both arms. PFS was superior in the lenalidomide arm regardless of dose reduction. Lenalidomide maintenance prolonged PFS and did not negatively impact HRQOL in patients with DLBCL despite TEAEs being more common, when compared with placebo., (© 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
37. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
- Author
-
Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, Salles GA, Tilly H, Fruchart C, Van Eygen K, Snauwaert S, Bonnet C, Haioun C, Thieblemont C, Bouabdallah R, Wu KL, Canioni D, Meignin V, Cartron G, and Houot R
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized adverse effects, Antigens, CD20 metabolism, Antineoplastic Agents, Immunological adverse effects, Disease-Free Survival, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Lenalidomide adverse effects, Lymphoma, B-Cell mortality, Lymphoma, B-Cell pathology, Lymphoma, Follicular mortality, Lymphoma, Follicular pathology, Male, Middle Aged, Neutropenia etiology, Recurrence, Survival Rate, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Lenalidomide therapeutic use, Lymphoma, B-Cell drug therapy, Lymphoma, Follicular drug therapy
- Abstract
Background: Lenalidomide plus rituximab is approved to treat patients with relapsed or refractory follicular lymphoma. Obinutuzumab has been shown to enhance antibody-dependent cellular cytotoxicity, phagocytosis, and direct B-cell killing better than rituximab. Our aim was to determine the activity and safety of lenalidomide plus obinutuzumab in previously treated patients with relapsed or refractory follicular lymphoma., Methods: In this multicentre, single-arm, phase 2 study, patients were enrolled from 24 Lymphoma Academic Research Organisation centres in France. Eligible patients (age ≥18 years) had histologically confirmed CD20-positive relapsed or refractory follicular lymphoma of WHO grade 1, 2, or 3a; an ECOG performance status of 0-2; and received at least one previous rituximab-containing therapy. Patients received oral lenalidomide (20 mg) plus intravenously infused obinutuzumab as induction therapy (1000 mg; six 28-day cycles), 1-year maintenance with lenalidomide (10 mg; 12 28-day cycles; days 2-22) plus obinutuzumab (1000 mg; alternate cycles), and 1-year maintenance with obinutuzumab (1000 mg; six 56-day cycles; day 1). The primary endpoint was the proportion of patients who achieved an overall response at induction end as per investigator assessment using the 1999 international working group criteria. The secondary endpoints were event-free survival, progression-free survival, overall survival, and safety. Analyses were per-protocol; the efficacy population included all patients who received at least one dose of both obinutuzumab and lenalidomide, and the safety population included all patients who received one dose of either investigational drug. The study is registered with ClinicalTrials.gov, number NCT01582776, and is ongoing but closed to accrual., Findings: Between June 11, 2014, and Dec 18, 2015, 89 patients were recruited and 86 patients were evaluable for efficacy and 88 for safety. Median follow-up was 2·6 years (IQR 2·2-2·8). 68 (79%) of 86 evaluable patients (95% CI 69-87) achieved an overall response at induction end, meeting the prespecified primary endpoint. At 2 years, event-free survival was 62% (95% CI 51-72), progression-free survival 65% (95% CI 54-74), duration of response 70% (95% CI 57-79), and overall survival 87% (95% CI 78-93). Complete response was achieved by 33 (38%, 95% CI 28-50) of 86 patients at induction end, and the proportion of patients achieving a best overall response was 70 (81%, 95% CI 72-89) and 72 (84%, 74-91) of 86 patients during induction and treatment, respectively. The most common adverse events were asthenia (n=54, 61%), neutropenia (n=38, 43%), bronchitis (n=36, 41%), diarrhoea (n=35, 40%), and muscle spasms (n=34, 39%). Neutropenia was the most common toxicity of grade 3 or more; four (5%) patients had febrile neutropenia. 57 serious adverse events were reported in 30 (34%) of 88 patients. The most common serious adverse events were basal cell carcinoma (n=5, 6%), febrile neutropenia (n=4, 5%), and infusion-related reaction (n=3, 3%). One patient died due to treatment-related febrile neutropenia., Interpretation: Our data shows that lenalidomide plus obinutuzumab is active in previously treated patients with relapsed or refractory follicular lymphoma, including those with early relapse, and has a manageable safety profile. Randomised trials of new immunomodulatory regimens, such as GALEN or using GALEN as a backbone, versus lenalidomide plus rituximab, are warranted., Funding: Lymphoma Academic Research Organisation, and Celgene and Roche., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
38. A new transcript in the TCRB locus unveils the human ortholog of the mouse pre-Dß1 promoter.
- Author
-
Lethé B, Snauwaert S, Bricard O, Schröder D, Gomard T, Hames G, Muller C, Lurquin C, Gauthy E, Essaghir A, Vandekerckhove B, and Coulie PG
- Subjects
- Animals, Humans, Mice, RNA, Messenger biosynthesis, Genes, T-Cell Receptor beta, Genetic Loci, Promoter Regions, Genetic, RNA, Messenger genetics, Transcription, Genetic
- Abstract
Introduction: While most transcripts arising from the human T Cell Receptor locus reflect fully rearranged genes, several germline transcripts have been identified. We describe a new germline transcript arising from the human TCRB locus., Methods: cDNA sequencing, promoter, and gene expression analyses were used to characterize the new transcript., Results: The new germline transcript encoded by the human TCRB locus consists of a new exon of 103 bp, which we named TRBX1 (X1), spliced with the first exon of gene segments Cß1 or Cß2. X1 is located upstream of gene segment Dß1 and is therefore deleted from a V-DJ rearranged TCRB locus. The X1-Cß transcripts do not appear to code for a protein. We define their transcription start and minimal promoter. These transcripts are found in populations of mature T lymphocytes from blood or tissues and in T cell clones with a monoallelic TCRB rearrangement. In immature thymocytes, they are already detectable in CD1a
- CD34+ CD4- CD8- cells, therefore before completion of the TCRB rearrangements., Conclusions: The X1 promoter appears to be the ortholog of the mouse pre-Dß1 promoter (PDß1). Like PDß1, its activation is regulated by Eß in T cells and might facilitate the TCRB rearrangement process by contributing to the accessibility of the Dß1 locus., (© 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.)- Published
- 2017
- Full Text
- View/download PDF
39. Humanized Mice to Study Human T Cell Development.
- Author
-
Bonte S, Snauwaert S, Vanhee S, Dolens AC, Taghon T, Vandekerckhove B, and Kerre T
- Subjects
- Animals, Hematopoietic Stem Cells metabolism, Humans, Mice, Models, Animal, T-Lymphocytes metabolism, Cell Differentiation, Hematopoietic Stem Cell Transplantation methods, Hematopoietic Stem Cells cytology, Heterografts, T-Lymphocytes cytology
- Abstract
While in vitro models exist to study human T cell development, they still lack the precise environmental stimuli, such as the exact combination and levels of cytokines and chemokines, that are present in vivo. Moreover, studying the homing of hematopoietic stem (HSC) and progenitor (HPC) cells to the thymus can only be done using in vivo models. Although species-specific differences exist, "humanized" models are generated to circumvent these issues. In this chapter, we focus on the humanized mouse models that can be used to study early T cell development. Models that study solely mature T cells, such as the SCID-PBL (Tary-Lehmann et al., Immunol Today 16:529-533) are therefore not discussed here, but have recently been reviewed (Shultz et al., Nat Rev Immunol 12:786-798).
- Published
- 2016
- Full Text
- View/download PDF
40. Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients.
- Author
-
Claus BO, Snauwaert S, Haerynck F, Van Daele S, De Baets F, and Schelstraete P
- Subjects
- Adult, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Colistin administration & dosage, Colistin adverse effects, Female, Gram-Negative Bacterial Infections complications, Humans, Infusions, Intravenous, Male, Paresthesia chemically induced, Anti-Bacterial Agents therapeutic use, Colistin therapeutic use, Cystic Fibrosis complications, Gram-Negative Bacterial Infections drug therapy
- Abstract
Case description The use of i.v. colistin reappeared recently for the treatment of multidrug-resistant Gram negative organisms in the intensive care and cystic fibrosis (CF) setting. According to the latest pharmacokinetic data, a loading dose and high antibiotic doses are given. Two cases of adverse events (paraesthesias, bad taste) were observed immediately after the start of infusion of a high dose of i.v. colistin in adult CF patients at the Ghent University Hospital. Conclusion Recommendations for optimal administration of i.v. colistin in adult CF patients are scarce. This article highlights the importance of mode of administration to avoid toxicity and relates it to recent pharmacokinetic/-dynamic literature.
- Published
- 2015
- Full Text
- View/download PDF
41. Specific Notch receptor-ligand interactions control human TCR-αβ/γδ development by inducing differential Notch signal strength.
- Author
-
Van de Walle I, Waegemans E, De Medts J, De Smet G, De Smedt M, Snauwaert S, Vandekerckhove B, Kerre T, Leclercq G, Plum J, Gridley T, Wang T, Koch U, Radtke F, and Taghon T
- Subjects
- Animals, Calcium-Binding Proteins genetics, Calcium-Binding Proteins immunology, Cell Differentiation genetics, Cell Differentiation immunology, Female, Humans, Intercellular Signaling Peptides and Proteins genetics, Intercellular Signaling Peptides and Proteins immunology, Jagged-1 Protein, Jagged-2 Protein, Male, Membrane Proteins genetics, Membrane Proteins immunology, Mice, Receptor, Notch1 genetics, Receptor, Notch3, Receptors, Antigen, T-Cell, alpha-beta genetics, Receptors, Antigen, T-Cell, gamma-delta genetics, Receptors, Notch genetics, Serrate-Jagged Proteins, Signal Transduction genetics, Thymus Gland cytology, Receptor, Notch1 immunology, Receptors, Antigen, T-Cell, alpha-beta immunology, Receptors, Antigen, T-Cell, gamma-delta immunology, Receptors, Notch immunology, Signal Transduction immunology, T-Lymphocytes immunology, Thymus Gland immunology
- Abstract
In humans, high Notch activation promotes γδ T cell development, whereas lower levels promote αβ-lineage differentiation. How these different Notch signals are generated has remained unclear. We show that differential Notch receptor-ligand interactions mediate this process. Whereas Delta-like 4 supports both TCR-αβ and -γδ development, Jagged1 induces mainly αβ-lineage differentiation. In contrast, Jagged2-mediated Notch activation primarily results in γδ T cell development and represses αβ-lineage differentiation by inhibiting TCR-β formation. Consistently, TCR-αβ T cell development is rescued through transduction of a TCR-β transgene. Jagged2 induces the strongest Notch signal through interactions with both Notch1 and Notch3, whereas Delta-like 4 primarily binds Notch1. In agreement, Notch3 is a stronger Notch activator and only supports γδ T cell development, whereas Notch1 is a weaker activator supporting both TCR-αβ and -γδ development. Fetal thymus organ cultures in JAG2-deficient thymic lobes or with Notch3-blocking antibodies confirm the importance of Jagged2/Notch3 signaling in human TCR-γδ differentiation. Our findings reveal that differential Notch receptor-ligand interactions mediate human TCR-αβ and -γδ T cell differentiation and provide a mechanistic insight into the high Notch dependency of human γδ T cell development.
- Published
- 2013
- Full Text
- View/download PDF
42. Can immunotherapy specifically target acute myeloid leukemic stem cells?
- Author
-
Snauwaert S, Vandekerckhove B, and Kerre T
- Abstract
Accumulating evidence supports the role of leukemic stem cells (LSCs) in the high relapse rate of acute myeloid leukemia (AML) patients. The clinical relevance of LSCs, which were originally characterized in xenograft models, has recently been confirmed by the finding that stem cell-like gene expression signatures can predict the clinical outcome of AML patients. The targeted elimination of LSCs might hence constitute an efficient therapeutic approach to AML. Here, we review immunotherapeutic strategies that target LSC-associated antigens, including T cell-mediated and monoclonal antibody-based regimens. Attention is given to the issue of antigen specificity because this is relevant to the therapeutic window and determines the superiority of LSC-targeting immunotherapy.
- Published
- 2013
- Full Text
- View/download PDF
43. In vitro generation of immune cells from pluripotent stem cells.
- Author
-
Vandekerckhove B, Vanhee S, Van Coppernolle S, Snauwaert S, Velghe I, Taghon T, Leclercq G, Kerre T, and Plum J
- Subjects
- Animals, Antigens, CD34, B-Lymphocytes cytology, CD4-Positive T-Lymphocytes cytology, CD8-Positive T-Lymphocytes cytology, Cell Culture Techniques, Cell Differentiation physiology, Hematopoietic Stem Cells cytology, Humans, Induced Pluripotent Stem Cells cytology, Killer Cells, Natural cytology, Mice, Stem Cell Transplantation, T-Lymphocytes cytology, Pluripotent Stem Cells cytology, T-Lymphocytes immunology
- Abstract
Stem cell transplant recipients and acquired or inherited immune-deficiency patients could benefit from the infusion of B, T and/or NK cells. These lymphoid cells can be generated in vitro from bone marrow derived CD34+CD45+ hematopoietic stem cells (HSC). The number of cells that can be obtained in this way is limited especially in the adult. An alternative source may therefore constitute human pluripotent stem cells (PSC) such as embryonic (hESC) or induced pluripotent stem cells (hiPSC). Here, we focus on present knowledge on the generation of lymphoid cells from hESC. The two main obstacles for the generation of clinically relevant immune cells are the failure to generate from hESC long-term repopulating HSC which could be kept in culture for prolonged time; and insufficient knowledge of the selection process which generates mature T cells from CD4 CD8 double positive (DP) precursors in vitro.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.